drugset
drugset / Trial / NCT06778850

A Phase I/IIa Clinical Study to Assess the Single and Multiple Ascending Doses of MDR-001 Tablets in Healthy Participants and Obese/ Overweight Participants

NCT06778850 ↗

Phase 1/2 Recruiting 131 enrolled MindRank AI Ltd
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To investigate the safety and tolerability after single and multiple ascending doses of MDR-001 Tablets administered orally in healthy participants and obese/ overweight participants.

Timeline

Start
2023-06-09
Primary completion
2025-07-15
Completion
2025-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject MDR-001 Small molecule — Oral

Indications

No indication recorded.